Merck (MRK) stock is in focus as the company posts a late-stage trial win for anti-PD-1 therapy, Keytruda, in endometrial cancer. Read more here.
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEX™ ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
Monotherapy in immunotherapy-ineligible patients improved median PFS to 9.7 vs 6.9 months versus physician’s-choice chemotherapy, with 50% vs 47% objective response rates. Combination therapy in PD-L1 ...
At the American Society of Clinical Oncology (ASCO) meeting, long-term follow-up from the KEYNOTE-522 trial reinforced the survival benefit of pembrolizumab (Keytruda)-based therapy in early-stage ...
Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall Street Journal. The move bolsters Merck’s pipeline with the COPD drug ...
OptiTROP-Lung06 demonstrated statistically significant, clinically meaningful PFS improvement for sac-TMT plus pembrolizumab versus pembrolizumab plus pemetrexed/platinum in first-line driver-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results